Posted on Tuesday, December 19, 2017 By Jonathan Rohll
Oxford, UK: Isansys Lifecare, a global health technology company, is delighted to announce its partnership with myHealth Sentinel (mHS) to offer its wireless, wearable, continuous patient data capture and analysis platform in Singapore.
Posted on Monday, December 11, 2017 By Jonathan Rohll
Wessex Clinical Research Network (CRN) and Wessex Academic Health Science Network (AHSN) have teamed up to support commercial innovators gather crucial evidence on their products. Their new Technology Support Programme (TSP) will help companies to access the NHS’s research infrastructure to obtain high quality evidence on the economic and health gains their products can bring.
Posted on Wednesday, November 29, 2017 By Jonathan Rohll
NASA to evaluate the use of Isansys’ physiological monitoring tools to learn how to monitor explorers as they travel into space. A NASA exploration scientist set off on his mission to Antarctica being monitored by the Patient Status Engine, a physiological data collection platform which provides monitoring of individuals wirelessly and in real-time.
Posted on Thursday, November 16, 2017 By Jonathan Rohll
BioSeed® has been designed to provide a platform for innovative life science companies to present and meet with sector specific early stage investors.
Posted on Monday, October 16, 2017 By Jonathan Rohll
Oxford, UK: Genomics plc today announced that it has entered into a collaborative deal with Biogen, Inc., the U.S.-based biotech, to work on multiple sclerosis (MS). Biogen is an international leader in drug therapies for MS, with the broadest MS portfolio in the industry.
Posted on Friday, October 06, 2017 By Jonathan Rohll
OBN Awards 2017 – Winners Recognised at Industry Leading Event
Abingdon, UK, 6 October 2017: – OBN (UK) Ltd, the membership organisation that supports the life sciences industry, are delighted to announce the winners of the prestigious OBN Awards 2017 that were presented last night in front of a sold-out audience of over 250 life science industry leaders at the Town Hall in Oxford.
The Awards, which are in their 9th year, celebrate the best of UK life sciences – from outstanding scientific innovation within biotech, medtech, digital, synthetic biology, to the companies that support the industry and the fundraisers that make it happen.
John Harris, CEO of OBN, said: “We received an outstanding number of entries this year; up a staggering 120% on last year, so competition was really tough. All of our winners and nominees this year are truly innovative and set a great example to the rest of the industry. We ...
Posted on Tuesday, June 13, 2017 By Jonathan Rohll
Oxford, UK - PsiOxus Therapeutics, Ltd. (PsiOxus), the cancer therapeutics company, today announced expansion of operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK. Additionally, PsiOxus announced the opening of a new US facility in Plymouth Meeting near Philadelphia, Pennsylvania. This dual expansion will allow PsiOxus to accelerate the research and development of novel immune-oncology products in both the UK and the US.
Posted on Thursday, April 20, 2017 By Jonathan Rohll
Abingdon, UK: OBN the membership organisation supporting the UK’s innovative life sciences companies, announces today the appointment of Bill Fleming to its Board of Directors, effective immediately
Posted on Wednesday, April 19, 2017 By Jonathan Rohll
Philadelphia, USA and Oxford, UK: Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately US$42,000,000 of its ADSs. Adaptimmune sold 7,000,000 ADSs at a price of $6.00 per ADS.
Posted on Friday, April 07, 2017 By Jonathan Rohll
Glasgow, Scotland: MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces today that it has raised $1.15 million in a financing round with existing investors.
Pages: Previous12NextReturn Top